NPPA and cardiac hypertrophy: miR‐195 inhibitor reversed the increased expression levels of miR‐195 (Figure 5A, ##P < .01 vs. miR‐195 mimics) and cardiac hypertrophy‐related indicators, ANP (Figure 5B, #P < .05 vs. miR‐195 mimics), BNP (Figure 5C, #P < .05 vs. miR‐195 mimics), β‐MHC (Figure 5D, ###P < .001 vs. miR‐195 mimics) levels.